NDAORALCAPSULE
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PRINCIPEN W/ PROBENECID is a fixed-dose oral capsule combining ampicillin (a broad-spectrum beta-lactam antibiotic) with probenecid (a uricosuric agent that inhibits renal tubular secretion). This combination enhances ampicillin bioavailability and prolongs serum half-life, enabling lower dosing frequencies. The product is indicated for bacterial infections where sustained ampicillin levels provide clinical advantage.
Pre-Launch
Early-stage product with undefined commercial trajectory; team composition and growth potential remain contingent on regulatory approval and market positioning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
This pre-launch product offers entry and mid-career professionals a rare opportunity to shape brand strategy from inception, including regulatory navigation, launch planning, and competitive positioning in the antibiotics space. Career growth depends heavily on successful FDA approval and market adoption post-launch.
Brand ManagerRegulatory Affairs Manager
Worked on PRINCIPEN W/ PROBENECID at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.